Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sun Jae | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Yoon, Eileen L. | - |
dc.contributor.author | Lee, Joong Min | - |
dc.contributor.author | Kim, Bo Hyun | - |
dc.contributor.author | Park, Sang Jong | - |
dc.contributor.author | Park, Young Min | - |
dc.contributor.author | Kim, Hong Soo | - |
dc.contributor.author | Lee, Se Hwan | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Lee, Jeong Il | - |
dc.contributor.author | Lee, Jin Woo | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Kim, Hyung Soo | - |
dc.contributor.author | Hong, Sun Pyo | - |
dc.date.accessioned | 2021-08-12T01:25:29Z | - |
dc.date.available | 2021-08-12T01:25:29Z | - |
dc.date.issued | 2013-02 | - |
dc.identifier.issn | 0036-5521 | - |
dc.identifier.issn | 1502-7708 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13961 | - |
dc.description.abstract | Objectives. To compare the efficacy of rescue therapies in lamivudine (LAM)-resistant chronic hepatitis B (CHB) infections including: (1) adefovir dipivoxil (ADV) monotherapy, (2) ADV plus LAM combination therapy and (3) entecavir (ETV) 1.0 mg monotherapy. Materials and methods. The authors designed a multicenter-retrospective study. Eight institutions participated in the study from Korea. Results. A total of 343 LAM-resistant CHB patients were enrolled. The proportion of patients with undetectable serum hepatitis B virus (HBV) DNA levels at month 24 after the initiation of rescue therapy was higher in the ADV plus LAM combination therapy group (39/64, 60.9%) than in the ADV monotherapy (50/126, 39.7%) and ETV 1.0 mg monotherapy (19/48, 39.6%) groups (p = 0.014). Mean serum HBV DNA levels at 24 months were 2.07 +/- 1.21 log(10) IU/ml in the ADV plus LAM combination therapy group, 2.74 +/- 1.74 log(10) IU/ml in the ADV monotherapy group and 3.08 +/- 1.97 log(10) IU/ml in the ETV 1.0 mg monotherapy group (p = 0.014). In multivariate analysis, a finding of undetectable serum HBV DNA level at 6 months and ADV plus LAM combination therapy (vs. ADV) was an independent factor for predicting undetectable serum HBV DNA at month 24 (odds ratio, 1.003; 95% confidence interval, 1.000-1.006; p = 0.026). Conclusions. ADV plus LAM combination therapy is more effective in reducing viral load than switching to ADV or ETV 1.0 mg in patients with LAM-resistant CHB. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Taylor & Francis | - |
dc.title | Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.3109/00365521.2012.722671 | - |
dc.identifier.wosid | 000313675600009 | - |
dc.identifier.bibliographicCitation | Scandinavian Journal of Gastroenterology, v.48, no.2, pp 196 - 204 | - |
dc.citation.title | Scandinavian Journal of Gastroenterology | - |
dc.citation.volume | 48 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 196 | - |
dc.citation.endPage | 204 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | RESCUE THERAPY | - |
dc.subject.keywordPlus | ENTECAVIR RESISTANCE | - |
dc.subject.keywordPlus | ADEFOVIR MONOTHERAPY | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | PLUS ADEFOVIR | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | SUBSTITUTIONS | - |
dc.subject.keywordPlus | DIPIVOXIL | - |
dc.subject.keywordPlus | GENOTYPES | - |
dc.subject.keywordAuthor | adefovir | - |
dc.subject.keywordAuthor | antiviral resistance | - |
dc.subject.keywordAuthor | chronic hepatitis B | - |
dc.subject.keywordAuthor | combination drug therapy | - |
dc.subject.keywordAuthor | entecavir | - |
dc.subject.keywordAuthor | lamivudine | - |
dc.subject.keywordAuthor | multicenter study | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.